文献速递间质性肺疾病呼吸道感染

吡非尼酮治疗新冠后肺纤维化:FIBRO-COVID 2期随机临床试验

Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.
PubMed 文献 · Eur Respir J · 2025-04-24

FIBRO-COVID 是一项西班牙多中心2期双盲安慰剂对照试验,评估吡非尼酮在重症COVID-19肺炎康复后出现纤维化间质改变患者中的疗效与安全性。113例患者按2:1随机接受吡非尼酮或安慰剂治疗24周,主要终点为FVC变化≥10%和/或HRCT纤维化评分下降的患者比例。结果显示吡非尼酮组与安慰剂组改善比例相似(79.7% vs 82.3%),肺功能及HRCT纤维化评分改善均未达统计学差异。

要点

  • 吡非尼酮24周治疗未显著改善新冠后肺纤维化患者的FVC或HRCT纤维化评分。
  • 主要终点改善比例吡非尼酮组79.7%、安慰剂组82.3%,两组相似。
  • 运动能力、不良事件及住院率两组相似,未报告死亡。

核心结论

  • 吡非尼酮治疗6个月后肺功能及HRCT纤维化评分的总体改善与安慰剂无显著差异。

研究设计与样本

  • 2期、双盲、安慰剂对照、西班牙多中心临床试验,患者按2:1随机接受吡非尼酮或安慰剂治疗24周。
  • 从119例合格患者中随机113例,分析103例(吡非尼酮组69例,安慰剂组34例)。

主要发现

  • 主要终点改善比例吡非尼酮组79.7%、安慰剂组82.3%。
  • 预测FVC平均变化吡非尼酮组+12.74±20.6%、安慰剂组+4.35±22.3%(p=0.071)。
  • HRCT纤维化评分(%)变化吡非尼酮组-5.44±3.69%、安慰剂组-2.57±2.59%(p=0.52)。
  • HRQoL临床意义改善比例吡非尼酮组55.2%、安慰剂组39.4%,无统计学差异。
  • 运动能力、不良事件及住院率两组相似,未报告死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with severe COVID-19 may develop lung fibrosis. Pirfenidone is an anti-fibrotic drug approved for idiopathic pulmonary fibrosis. The efficacy and safety of pirfenidone in patients with fibrotic interstitial lung changes after recovery from severe COVID-19 pneumonia were evaluated. METHODS: This was a phase 2, double-blind, placebo-controlled, Spanish multicentre clinical trial. Patients were randomised to receive pirfenidone or placebo (2:1) for 24 weeks. The primary end-point was the proportion of patients that improved, considered when percentage change in forced vital capacity (FVC) was ≥10% and/or any reduction in the fibrotic score on chest high-resolution computed tomography (HRCT). Secondary end-points included health-related quality of life (HRQoL), exercise capacity and drug safety profile. RESULTS: From 119 eligible patients, 113 were randomised and 103 were analysed (pirfenidone n=69 and placebo n=34). Most patients were male (73.5%) and were receiving low-dose prednisone; mean age was 63.7 years and mean body mass index was 29 kg·m-2. The percentage of patients that improved was similar in the pirfenidone and placebo groups (79.7% versus 82.3%, respectively). The mean predicted FVC increased by 12.74±20.6% with pirfenidone and 4.35±22.3% with placebo (p=0.071), and the HRCT (%) fibrotic score decreased by 5.44±3.69% with pirfenidone and 2.57±2.59% with placebo (p=0.52). Clinically meaningful improvement in HRQoL was not statistically different (55.2% in the pirfenidone group and 39.4% in the placebo group). Exercise capacity, adverse events and hospitalisations were similar between groups. No deaths were reported. CONCLUSIONS: The overall improvements in lung function and HRCT fibrotic score after 6 months with pirfenidone were not significantly different than with placebo.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Bermudo-Peloche G, Del Rio B, Vicens-Zygmunt V, et al. Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial. Eur Respir J. 2025. PMID: 40154560. doi:10.1183/13993003.02249-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。